Parnax Lab (BOM:506128) ROCE % : 15.70% (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Parnax Lab ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Parnax Lab's annualized ROCE % for the quarter that ended in Mar. 2024 was 15.70%.

Parnax Lab ROCE % Historical Data

The historical data trend for Parnax Lab's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnax Lab ROCE % Chart

Parnax Lab Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

4.40

9.19

28.03

22.30

18.41

Parnax Lab Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															16.67	25.05	16.49	18.76	15.70

Parnax Lab ROCE % Calculation

Parnax Lab's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	173.955	/	( ( (1450.729 - 630.417)	+	(1887.658 - 818.311) )	/ 2 )
	=	173.955	/	( (820.312	+	1069.347)	/ 2 )
	=	173.955	/	944.8295
	=	18.41 %

Parnax Lab's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	167.924	/	( ( (0 - 0)	+	(1887.658 - 818.311) )	/ 1 )
	=	167.924	/	( ( 0	+	1069.347 )	/ 1 )
	=	167.924	/	1069.347
	=	15.70 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Parnax Lab (BOM:506128) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Parnax Lab ROCE % Related Terms

Thank you for viewing the detailed overview of Parnax Lab's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnax Lab (BOM:506128) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnax Lab Ltd (BOM:506128) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022

Website

https://www.naxparlab.com

Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.

Parnax Lab (BOM:506128) Headlines

No Headlines